NAD Challenges 'Personalized' Claims for Compounded Tirzepatide+

A familiar marketing word has become the center of a specific advertising challenge: "personalized." On November 4, BBB National Programs' National Advertising Division recommended that Good Life Meds discontinue health benefit and personalization claims for its compounded Tirzepatide+ products. Eli Lilly brought the challenge. Good Life said it disagreed with many aspects of the decision but would comply with the recommendations, according to NAD's public summary. [1]

What the review actually was

NAD is an independent advertising self-regulatory body, not FDA, a court or a government agency. Its review concerned Good Life's advertising for a particular compounded product. The announcement is not an FDA order, a drug approval decision or a general ban on compounded tirzepatide. Those distinctions matter because a headline about claims being discontinued can otherwise sound like a decision about whether every prescription may be filled. [1][2]

The publicly available primary source is NAD's decision summary. The full decision is in BBB National Programs' subscription archive. The summary describes the claims, the evidence NAD considered, its recommendations and the advertiser's response. It does not establish that Good Life has already completed every recommended website change. [1][2]

NAD's broader procedures also distinguish an advertiser agreeing to comply from a referral to a regulator. The program says it refers matters to the Federal Trade Commission when advertisers decline to participate or comply. Here, the public statement records Good Life's agreement to comply. It does not announce an FTC enforcement action. [1][2]

The evidence problem was the finished product

The challenged health benefit claims concerned weight loss, energy, blood sugar control and preservation of lean muscle. NAD found that the advertising as a whole conveyed benefits for Tirzepatide+ as a finished compounded product, rather than merely describing an ingredient. These are the claims being reviewed, not benefits established by this article. [1]

Good Life submitted clinical literature on tirzepatide, separate literature on additive ingredients and real-world evidence that included a Gallup survey and retrospective cohort studies. NAD did not say there was no literature. It said the evidence was not a good fit for the claims. That is a more specific finding, and a more useful one for anyone reviewing a product page. [1]

According to the summary, much of the tirzepatide literature concerned Lilly's FDA-approved products. The record did not bridge the gap between ingredient-level evidence and Tirzepatide+ as compounded. The survey and cohort studies did not examine Tirzepatide+. NAD also said the record contained no evidence evaluating the safety of combining tirzepatide with the additives. [1]

An absence of supporting evidence in this record is not the same as a finding that every combination causes harm. It does mean that the claims at issue were not substantiated to NAD's satisfaction. NAD recommended discontinuing the express benefit claims and modifying advertising to avoid unsupported implied claims about safety, effectiveness and significant weight loss results. The distinction keeps the report tied to what the review found. [1]

Why "personalized" did not pass

Lilly also challenged descriptions including "personalized medication," "tailored to meet individual patient needs" and "compounded for your unique needs." NAD concluded that the advertising conveyed an individualization message that overstated the underlying process. [1]

The summary expressly recognizes that a physician may choose among available formulations and treatment options and adjust a patient's plan over time. NAD's conclusion was that this does not mean the product itself is individually created or formulated for that patient. Its recommendation targeted claims including "personalized," "custom formulated" and the patient-specific phrases above. [1]

That distinction separates clinical decision-making from a manufacturing representation. A clinician can make an individual treatment decision without every description of the resulting product becoming supported. For a clinic owner, the question is what the advertising tells a reader about the product itself, not simply whether a licensed professional takes part in prescribing it. That is the practical reading of this case, rather than a new legal rule announced here. [1]

The larger substantiation principle

FTC's Health Products Compliance Guidance provides a separate government source for the general evidence framework. It says advertising must be truthful, not misleading and adequately supported. It also says marketers must consider express claims, implied claims and the overall impression an advertisement conveys. This is existing FTC guidance, not a new November policy. [3]

The guidance discusses whether research fits the advertised product and claim. Relevant differences can include formulation, ingredient combinations, the population studied and the result being promised. It cautions against assuming that evidence about an ingredient necessarily substantiates a finished product's benefits. The Good Life summary illustrates a similar evidence-fit problem in one self-regulatory case. It does not establish that FTC investigated or endorsed NAD's conclusions in this matter. [1][3]

A long reference list therefore is not the same thing as a supported sentence. The missing link may be between the tested product and the advertised formulation, or between the measured result and the benefit a consumer reasonably takes away. Counting studies without checking that link would miss the central issue described in NAD's summary. [1][3]

A concrete review for clinic operators

The useful response is a claim-by-claim review, not substituting one reassuring adjective for another. Read a landing page together with its photographs, headings, testimonials and linked advertising. FTC's guidance focuses on the overall impression, so a narrow disclaimer should not be treated as the whole message. [3]

For each benefit statement, identify the exact product being described and the evidence offered for that statement. Ask whether the research evaluates that formulation or something different. Keep a description of an individual consultation separate from a claim that the medication itself is individually formulated. If the evidence or wording is uncertain, take that specific question to qualified advertising counsel and the responsible clinical or pharmacy professionals. [1][3]

NAD's summary also says Good Life voluntarily and permanently discontinued some claims during the inquiry. NAD treats those withdrawn claims for compliance purposes as though it had recommended their discontinuation. The advertiser's stated disagreement and its commitment to comply both belong in the account; omitting either would make the outcome sound simpler than the published record. [1]

A study about an ingredient is not automatically evidence for every finished product containing it.

What it means for a clinic: The Good Life case puts evidence fit and the meaning of "personalized" under a clear spotlight. Keep the result in proportion: it is a self-regulatory advertising recommendation concerning one advertiser, with a stated commitment to comply. The operational lesson is to connect each public claim to the product, process and evidence that actually support it, rather than relying on an ingredient's reputation or a clinician's involvement to do that work. [1][2][3]